Suvretta Capital Boosts Regeneron Pharmaceuticals Holdings

Hedge fund increases stake in biotech firm by over 100% in Q3

Mar. 14, 2026 at 11:08am

Got story updates? Submit your updates here. ›

Suvretta Capital Management LLC, a hedge fund based in New York, significantly increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) during the third quarter of 2025. The fund added 9,100 shares, representing a 105.4% increase in its position in the biopharmaceutical company.

Why it matters

Regeneron is a leading biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. Suvretta's substantial investment in the company signals the hedge fund's confidence in Regeneron's long-term growth potential.

The details

According to a recent SEC filing, Suvretta Capital Management lifted its stake in Regeneron Pharmaceuticals by 105.4% during the third quarter, bringing its total holdings to 17,730 shares. The fund's position in Regeneron was valued at nearly $10 million as of the end of the reporting period.

  • Suvretta Capital Management increased its Regeneron Pharmaceuticals holdings during the third quarter of 2025.

The players

Suvretta Capital Management LLC

A New York-based hedge fund that focuses on investments in the healthcare and technology sectors.

Regeneron Pharmaceuticals, Inc.

A biopharmaceutical company known for its innovative drug discovery technologies and pipeline of biologic therapies.

Got photos? Submit your photos here. ›

The takeaway

Suvretta Capital's substantial investment in Regeneron Pharmaceuticals underscores the hedge fund's confidence in the biotech firm's long-term growth prospects. This move highlights the continued investor interest in Regeneron's innovative pipeline and its potential to deliver value for shareholders.